
Ghana’s healthcare sector is experiencing a dual push for excellence through high-level advocacy for professional standards and international research partnerships. The Asantehene, Otumfuo Osei Tutu II, has called on the government to increase investment in the training and deployment of pharmacists, describing a well-trained pharmaceutical workforce as the backbone of any effective health system. Simultaneously, the Kwame Nkrumah University of Science and Technology (KNUST) has solidified Ghana’s role in global medical innovation by joining the DENSTAR Project, an international consortium dedicated to the licensure and deployment of a groundbreaking dengue vaccine.
Speaking at a forum marking the 90th anniversary of the Pharmaceutical Society of Ghana, the Asantehene emphasized that the pursuit of quality healthcare is inseparable from the professional integrity of pharmacists. He urged practitioners to strictly adhere to ethical standards and resist any compromise on the quality of service. The event, which explored the evolution of pharmacy education in Ghana, also recognized the leadership of Prof. Rita Akosua Dickson, Vice Chancellor of KNUST, highlighting the critical intersection between academic excellence and pharmaceutical practice.
This academic leadership is further evidenced by KNUST’s participation in the €11 million DENSTAR Project, funded by the GH EDCTP3 JU and backed by the European Union. Commencing in June 2026, this initiative brings together ten institutions from nine countries to evaluate the safety and efficacy of "DengiAll," a tetravalent live-attenuated dengue vaccine. By facilitating clinical trials specifically within sub-saharan Africa, the project aims to ensure that life-saving treatments are tailored to the needs of African populations, potentially reducing the global burden of dengue infections significantly.
Together, these developments signal a transformative period for Ghana’s health landscape. While the Asantehene’s advocacy underscores the necessity of human resource development and professional ethics, KNUST’s involvement in high-stakes clinical research demonstrates the country's capacity to contribute to global public health solutions. Moving forward, the combination of a disciplined pharmaceutical workforce and cutting-edge medical research will be vital for achieving the nation’s long-term healthcare objectives and improving health outcomes across the continent.
This story touches markets covered on Anansi Intelligence ↗.
Continue exploring similar stories